Cite

HARVARD Citation

    Tomasevic, Z. et al. (n.d.). 84TiPHER-Seq: A blood-based genomic screening study to identify HER2 mutation-positive patients for enrollment into clinical trials with the pan-HER inhibitor neratinib. Annals of oncology. p. . [Online]. 
  
Back to record